MY CONTENT

Clinical follow-up of 144 of 154 patients who survived the admission period (January 1995–August 2006) was for a mean of 9.8 years. Aneurysm size of 15 mm was the most important independent predictor for retreatment. Nine rebleeds occurred in 106 patients who initially presented with SAH after a median follow-up of 8.3 years. Eight patients died of aneurysm-related adverse events: 3 of rebleed and 5 of progressive mass effect. Life-long MRA follow-up at yearly intervals is recommended.